InMed Pharmaceuticals Inc. (INM)
USD 1.87
(1.62%)
USD 1.87
(1.62%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 | -7.67 Million USD | 3.42% |
| 2023 | -7.94 Million USD | 57.27% |
| 2022 | -18.6 Million USD | -82.35% |
| 2021 | -10.2 Million USD | -14.09% |
| 2020 | -8.94 Million CAD | 10.69% |
| 2019 | -10.01 Million CAD | -49.22% |
| 2018 | -6.7 Million USD | -95.01% |
| 2017 | -3.43 Million CAD | -87.22% |
| 2016 | -1.83 Million CAD | 46.87% |
| 2015 | -3.45 Million CAD | -200.14% |
| 2014 | -1.15 Million CAD | -2365.21% |
| 2013 | -46.73 Thousand CAD | 75.39% |
| 2012 | -189.91 Thousand CAD | 41.65% |
| 2011 | -325.46 Thousand CAD | 2.78% |
| 2010 | -334.78 Thousand CAD | 68.41% |
| 2009 | -1.05 Million CAD | -14.92% |
| 2008 | -922.26 Thousand CAD | 50.79% |
| 2007 | -1.87 Million CAD | -47.28% |
| 2006 | -1.27 Million CAD | 54.2% |
| 2005 | -2.77 Million CAD | -82.82% |
| 2004 | -1.51 Million CAD | -23.53% |
| 2003 | -1.23 Million CAD | 54.63% |
| 2002 | -2.71 Million CAD | 36.47% |
| 2001 | -4.26 Million CAD | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q3 | -1.72 Million USD | -16.55% |
| 2024 Q4 | -7.65 Million USD | -12.47% |
| 2024 Q1 | -2.53 Million USD | -649.67% |
| 2024 Q2 | -1.47 Million USD | 41.73% |
| 2023 Q1 | -3.51 Million USD | 55.4% |
| 2023 Q2 | -2.1 Million USD | 40.14% |
| 2023 Q4 | -338.39 Thousand USD | 83.06% |
| 2023 Q3 | -1.99 Million USD | 4.91% |
| 2023 FY | -7.94 Million USD | 66.05% |
| 2022 Q1 | -2.97 Million USD | 8.81% |
| 2022 Q4 | -7.87 Million USD | -126.43% |
| 2022 FY | -23.4 Million USD | -121.6% |
| 2022 Q3 | -3.47 Million USD | 18.85% |
| 2022 Q2 | -4.28 Million USD | -44.12% |
| 2021 Q1 | -1.59 Million CAD | 18.06% |
| 2021 FY | -10.56 Million USD | -21.42% |
| 2021 Q3 | -3.1 Million USD | -38.23% |
| 2021 Q4 | -3.25 Million USD | -5.07% |
| 2021 Q2 | -2.24 Million USD | -40.32% |
| 2020 Q1 | -2.8 Million CAD | 16.69% |
| 2020 FY | -8.69 Million CAD | 11.54% |
| 2020 Q3 | -2.02 Million CAD | 18.83% |
| 2020 Q2 | -2.49 Million CAD | 11.12% |
| 2020 Q4 | -1.95 Million CAD | 3.59% |
| 2019 Q2 | -1.94 Million CAD | 11.41% |
| 2019 Q4 | -3.36 Million CAD | -28.8% |
| 2019 Q1 | -2.19 Million CAD | 1.22% |
| 2019 FY | -9.83 Million CAD | -46.6% |
| 2019 Q3 | -2.61 Million CAD | -34.19% |
| 2018 Q1 | -1.46 Million CAD | 1.64% |
| 2018 FY | -6.7 Million USD | -95.01% |
| 2018 Q4 | -2.22 Million CAD | -35.11% |
| 2018 Q3 | -1.64 Million CAD | -34.24% |
| 2018 Q2 | -1.22 Million CAD | 16.34% |
| 2017 Q4 | -1.49 Million CAD | -60.3% |
| 2017 Q3 | -930.53 Thousand CAD | -33.17% |
| 2017 Q2 | -698.78 Thousand CAD | -119.78% |
| 2017 Q1 | -317.94 Thousand CAD | 19.47% |
| 2017 FY | -3.43 Million CAD | -87.22% |
| 2016 Q4 | -394.81 Thousand CAD | -34.0% |
| 2016 Q2 | -558.56 Thousand CAD | -8.18% |
| 2016 Q1 | -516.35 Thousand CAD | 57.54% |
| 2016 FY | -1.83 Million CAD | 46.87% |
| 2016 Q3 | -294.64 Thousand CAD | 47.25% |
| 2015 Q1 | -584.42 Thousand CAD | 42.46% |
| 2015 Q2 | -487.82 Thousand CAD | 16.53% |
| 2015 Q4 | -1.21 Million CAD | 5.05% |
| 2015 FY | -3.45 Million CAD | -200.14% |
| 2015 Q3 | -1.28 Million CAD | -162.56% |
| 2014 FY | -1.15 Million CAD | -2365.21% |
| 2014 Q3 | -92.31 Thousand CAD | -162.09% |
| 2014 Q4 | -1.01 Million CAD | -1000.22% |
| 2014 Q1 | -10.98 Thousand CAD | 51.72% |
| 2014 Q2 | -35.22 Thousand CAD | -220.68% |
| 2013 Q4 | -22.75 Thousand CAD | -198.54% |
| 2013 FY | -46.73 Thousand CAD | 75.39% |
| 2013 Q1 | -22.94 Thousand CAD | 76.69% |
| 2013 Q3 | -7621.01 CAD | -227.81% |
| 2013 Q2 | 5962.83 CAD | 125.99% |
| 2012 Q4 | -98.43 Thousand CAD | -334.53% |
| 2012 Q3 | -22.65 Thousand CAD | 13.71% |
| 2012 Q2 | -26.25 Thousand CAD | 34.93% |
| 2012 Q1 | -40.34 Thousand CAD | -308.27% |
| 2012 FY | -189.91 Thousand CAD | 41.65% |
| 2011 FY | -325.46 Thousand CAD | 2.78% |
| 2011 Q3 | -219.56 Thousand CAD | -460.51% |
| 2011 Q4 | -9880.89 CAD | 95.5% |
| 2011 Q2 | -39.17 Thousand CAD | 25.36% |
| 2011 Q1 | -52.47 Thousand CAD | 24.18% |
| 2010 Q3 | -92.92 Thousand CAD | -6.06% |
| 2010 Q4 | -69.21 Thousand CAD | 25.52% |
| 2010 Q1 | -78.83 Thousand CAD | -184.77% |
| 2010 Q2 | -87.61 Thousand CAD | -11.13% |
| 2010 FY | -334.78 Thousand CAD | 68.41% |
| 2009 Q1 | -965.66 Thousand CAD | -305.58% |
| 2009 Q3 | -93.35 Thousand CAD | 64.0% |
| 2009 Q2 | -259.29 Thousand CAD | 73.15% |
| 2009 Q4 | 93 Thousand CAD | 199.62% |
| 2009 FY | -1.05 Million CAD | -14.92% |
| 2008 Q1 | -269.52 Thousand CAD | 68.25% |
| 2008 Q4 | -238.09 Thousand CAD | -26.83% |
| 2008 Q3 | -187.72 Thousand CAD | 55.75% |
| 2008 Q2 | -424.25 Thousand CAD | -57.41% |
| 2008 FY | -922.26 Thousand CAD | 50.79% |
| 2007 Q2 | -580.85 Thousand CAD | -86.54% |
| 2007 Q4 | -848.85 Thousand CAD | -271.79% |
| 2007 Q1 | -311.39 Thousand CAD | -49.45% |
| 2007 Q3 | -228.31 Thousand CAD | 60.69% |
| 2007 FY | -1.87 Million CAD | -47.28% |
| 2006 Q1 | -355.93 Thousand CAD | 73.68% |
| 2006 Q3 | -447.61 Thousand CAD | -69.35% |
| 2006 Q2 | -264.31 Thousand CAD | 25.74% |
| 2006 Q4 | -208.36 Thousand CAD | 53.45% |
| 2006 FY | -1.27 Million CAD | 54.2% |
| 2005 FY | -2.77 Million CAD | -82.82% |
| 2005 Q4 | -1.35 Million CAD | -319.63% |
| 2005 Q3 | -322.22 Thousand CAD | 14.76% |
| 2005 Q2 | -378.03 Thousand CAD | 45.91% |
| 2005 Q1 | -698.86 Thousand CAD | 0.19% |
| 2004 Q1 | -274.18 Thousand CAD | 33.52% |
| 2004 FY | -1.51 Million CAD | -23.53% |
| 2004 Q4 | -700.2 Thousand CAD | -172.63% |
| 2004 Q3 | -256.83 Thousand CAD | 17.08% |
| 2004 Q2 | -309.72 Thousand CAD | -12.97% |
| 2003 Q1 | -301.79 Thousand CAD | 45.13% |
| 2003 FY | -1.23 Million CAD | 54.63% |
| 2003 Q4 | -412.43 Thousand CAD | -94.72% |
| 2003 Q2 | -261.76 Thousand CAD | 13.27% |
| 2003 Q3 | -211.81 Thousand CAD | 19.08% |
| 2002 Q1 | -744.59 Thousand CAD | 0.0% |
| 2002 Q2 | -730.47 Thousand CAD | 1.9% |
| 2002 FY | -2.71 Million CAD | 36.47% |
| 2002 Q4 | -549.98 Thousand CAD | 17.91% |
| 2002 Q3 | -669.99 Thousand CAD | 8.28% |
| 2001 FY | -4.26 Million CAD | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| AbCellera Biologics Inc. | -146.39 Million USD | 94.757% |
| Alkermes plc | 355.75 Million USD | 102.158% |
| Agenus Inc. | -245.76 Million USD | 96.877% |
| Aptorum Group Limited | -2.82 Million USD | -171.735% |
| Ardelyx, Inc. | -66.06 Million USD | 88.382% |
| Dyadic International, Inc. | -6.79 Million USD | -12.951% |
| Eton Pharmaceuticals, Inc. | -936 Thousand USD | -720.037% |
| Lantern Pharma Inc. | -15.96 Million USD | 51.912% |
| Inhibikase Therapeutics, Inc. | -19.02 Million USD | 59.664% |
| Novavax, Inc. | -545.06 Million USD | 98.592% |
| Janux Therapeutics, Inc. | -58.29 Million USD | 86.833% |
| Pyxis Oncology, Inc. | -73.79 Million USD | 89.598% |
| TransCode Therapeutics, Inc. | -18.54 Million USD | 58.614% |
| Ocuphire Pharma, Inc. | -9.98 Million USD | 23.137% |
| Outlook Therapeutics, Inc. | -58.98 Million USD | 86.987% |
| Madrigal Pharmaceuticals, Inc. | -373.63 Million USD | 97.946% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 68.464% |
| SELLAS Life Sciences Group, Inc. | -37.34 Million USD | 79.444% |
| Syros Pharmaceuticals, Inc. | -164.57 Million USD | 95.336% |
| Barinthus Biotherapeutics plc | -73.34 Million USD | 89.535% |
| Windtree Therapeutics, Inc. | -20.29 Million USD | 62.173% |
| Xeris Biopharma Holdings, Inc. | -62.25 Million USD | 87.671% |
| Clearside Biomedical, Inc. | -32.48 Million USD | 76.372% |
| C4 Therapeutics, Inc. | -132.49 Million USD | 94.207% |
| Alnylam Pharmaceuticals, Inc. | -440.24 Million USD | 98.257% |
| AlloVir, Inc. | -190.41 Million USD | 95.969% |
| Arrowhead Pharmaceuticals, Inc. | -205.27 Million USD | 96.261% |
| VYNE Therapeutics Inc. | -28.45 Million USD | 73.023% |
| Bicycle Therapeutics plc | -180.66 Million USD | 95.751% |
| BioXcel Therapeutics, Inc. | -179.05 Million USD | 95.713% |
| ChromaDex Corporation | -4.93 Million USD | -55.438% |
| Chimerix, Inc. | -82.09 Million USD | 90.65% |
| Corbus Pharmaceuticals Holdings, Inc. | -44.6 Million USD | 82.792% |
| Caribou Biosciences, Inc. | -102.07 Million USD | 92.48% |
| CRISPR Therapeutics AG | -153.61 Million USD | 95.003% |
| Precision BioSciences, Inc. | -61.31 Million USD | 87.483% |
| Fate Therapeutics, Inc. | -160.92 Million USD | 95.23% |
| Fortress Biotech, Inc. | -60.63 Million USD | 87.342% |
| Fortress Biotech, Inc. | -60.63 Million USD | 87.342% |
| HOOKIPA Pharma Inc. | -81.58 Million USD | 90.591% |
| ImmuCell Corporation | -5.77 Million USD | -32.919% |
| IDEAYA Biosciences, Inc. | -112.96 Million USD | 93.205% |
| Immix Biopharma, Inc. | -15.42 Million USD | 50.243% |
| Incyte Corporation | 597.59 Million USD | 101.284% |
| Innoviva, Inc. | 179.72 Million USD | 104.271% |
| IO Biotech, Inc. | -86.08 Million USD | 91.084% |
| Jaguar Health, Inc. | -41.3 Million USD | 81.415% |
| Keros Therapeutics, Inc. | -152.99 Million USD | 94.983% |
| Ligand Pharmaceuticals Incorporated | 52.15 Million USD | 114.717% |
| ContextLogic Inc. | -317 Million USD | 97.579% |
| MiMedx Group, Inc. | 67.43 Million USD | 111.381% |
| MEI Pharma, Inc. | 17.77 Million USD | 143.174% |
| NextCure, Inc. | -62.72 Million USD | 87.763% |
| Onconetix, Inc. | -37.4 Million USD | 79.482% |
| Oncternal Therapeutics, Inc. | -39.47 Million USD | 80.558% |
| Opthea Limited | -220.24 Million USD | 96.515% |
| Psyence Biomedical Ltd. | -51.15 Million USD | 84.997% |
| Vaxcyte, Inc. | -402.26 Million USD | 98.092% |
| PDS Biotechnology Corporation | -42.94 Million USD | 82.126% |
| Precigen, Inc. | -95.9 Million USD | 91.997% |
| Pharming Group N.V. | -10.54 Million USD | 27.232% |
| Phathom Pharmaceuticals, Inc. | -201.59 Million USD | 96.193% |
| Pieris Pharmaceuticals, Inc. | -24.54 Million USD | 68.726% |
| PureTech Health plc | -65.69 Million USD | 88.317% |
| Rigel Pharmaceuticals, Inc. | -25.09 Million USD | 69.409% |
| Avidity Biosciences, Inc. | -212.22 Million USD | 96.383% |
| Reviva Pharmaceuticals Holdings, Inc. | -24.33 Million USD | 68.464% |
| Sangamo Therapeutics, Inc. | -257.83 Million USD | 97.023% |
| Sol-Gel Technologies Ltd. | -27.23 Million USD | 71.82% |
| Acelyrin, Inc. | -381.64 Million USD | 97.989% |
| Salarius Pharmaceuticals, Inc. | -12.54 Thousand USD | -61095.405% |
| Summit Therapeutics Inc. | -614.92 Million USD | 98.752% |
| Sensei Biotherapeutics, Inc. | -34.1 Million USD | 77.492% |
| Senti Biosciences, Inc. | -92.91 Million USD | 91.74% |
| Stoke Therapeutics, Inc. | -104.69 Million USD | 92.669% |
| Elevation Oncology, Inc. | -45.7 Million USD | 83.206% |
| Alaunos Therapeutics, Inc. | -35.14 Million USD | 78.157% |
| Telomir Pharmaceuticals, Inc. Common Stock | -13.07 Million USD | 41.282% |
| Entrada Therapeutics, Inc. | -6.68 Million USD | -14.818% |
| VistaGen Therapeutics, Inc. | -29.36 Million USD | 73.859% |
| Kintara Therapeutics, Inc. | -8.5 Million USD | 9.71% |
| Wave Life Sciences Ltd. | -57.51 Million USD | 86.654% |
| Seer, Inc. | -86.27 Million USD | 91.104% |
| Verrica Pharmaceuticals Inc. | -66.99 Million USD | 88.543% |
| Aadi Bioscience, Inc. | -65.76 Million USD | 88.329% |
| ESSA Pharma Inc. | -26.58 Million USD | 71.125% |
| GlycoMimetics, Inc. | -36.89 Million USD | 79.199% |
| GT Biopharma, Inc. | -7.59 Million USD | -1.034% |
| Inhibrx Biosciences, Inc. | -241.36 Million USD | 96.82% |
| Akebia Therapeutics, Inc. | -51.92 Million USD | 85.218% |
| Catalyst Pharmaceuticals, Inc. | 71.41 Million USD | 110.749% |
| Longboard Pharmaceuticals, Inc. | -54.42 Million USD | 85.896% |
| Orchestra BioMed Holdings, Inc. | -49.12 Million USD | 84.374% |
| Alzamend Neuro, Inc. | -9.94 Million USD | 22.841% |
| Sorrento Therapeutics, Inc. | -572.84 Million USD | 98.66% |
| TRACON Pharmaceuticals, Inc. | -3.58 Million USD | -113.923% |
| Viracta Therapeutics, Inc. | -51.05 Million USD | 84.967% |
| Rocket Pharmaceuticals, Inc. | -245.59 Million USD | 96.875% |
| Aptose Biosciences Inc. | -51.2 Million USD | 85.011% |
| ZyVersa Therapeutics, Inc. | -98.29 Million USD | 92.192% |
| Soligenix, Inc. | -6.14 Million USD | -24.994% |
| Century Therapeutics, Inc. | -136.67 Million USD | 94.384% |
| Kura Oncology, Inc. | -152.63 Million USD | 94.971% |
| TScan Therapeutics, Inc. | -89.21 Million USD | 91.397% |
| Intensity Therapeutics, Inc. | -10.53 Million USD | 27.163% |
| Ocean Biomedical, Inc. | 565.47 Thousand USD | 1457.375% |
| CytomX Therapeutics, Inc. | -569 Thousand USD | -1248.954% |
| Autolus Therapeutics plc | -208.38 Million USD | 96.317% |
| Mineralys Therapeutics, Inc. | -71.89 Million USD | 89.324% |
| EyePoint Pharmaceuticals, Inc. | -70.79 Million USD | 89.158% |
| Eterna Therapeutics Inc. | -21.66 Million USD | 64.577% |
| Adaptive Biotechnologies Corporation | -225.25 Million USD | 96.592% |
| GRI Bio, Inc. | -13.03 Million USD | 41.125% |
| Xenetic Biosciences, Inc. | -4.13 Million USD | -85.643% |
| Tenaya Therapeutics, Inc. | -124.08 Million USD | 93.814% |
| IGM Biosciences, Inc. | -246.41 Million USD | 96.885% |
| INmune Bio, Inc. | -30 Million USD | 74.422% |
| Heron Therapeutics, Inc. | -110.55 Million USD | 93.058% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 81.809% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 51.913% |
| Entero Therapeutics, Inc. | -15.79 Million USD | 51.405% |
| Milestone Pharmaceuticals Inc. | -59.68 Million USD | 87.14% |
| X4 Pharmaceuticals, Inc. | -101.16 Million USD | 92.413% |
| Atara Biotherapeutics, Inc. | -276.12 Million USD | 97.22% |
| Coherus BioSciences, Inc. | -237.89 Million USD | 96.774% |
| Verastem, Inc. | -87.36 Million USD | 91.215% |
| Abeona Therapeutics Inc. | -54.18 Million USD | 85.835% |
| Pliant Therapeutics, Inc. | -161.33 Million USD | 95.243% |
| Tonix Pharmaceuticals Holding Corp. | -116.65 Million USD | 93.42% |
| Histogen Inc. | -10.62 Million USD | 27.732% |
| Aprea Therapeutics, Inc. | -14.28 Million USD | 46.275% |
| Surrozen, Inc. | -43.04 Million USD | 82.167% |
| Organovo Holdings, Inc. | -14.67 Million USD | 47.682% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -50.885% |
| Ovid Therapeutics Inc. | -52.33 Million USD | 85.335% |
| Panbela Therapeutics, Inc. | -25.26 Million USD | 69.617% |
| CASI Pharmaceuticals, Inc. | -26.93 Million USD | 71.507% |
| Cadrenal Therapeutics, Inc. Common Stock | -8.35 Million USD | 8.155% |
| Centessa Pharmaceuticals plc | -151.08 Million USD | 94.92% |
| Hepion Pharmaceuticals, Inc. | -48.92 Million USD | 84.312% |
| Arcturus Therapeutics Holdings Inc. | -29.72 Million USD | 74.178% |
| BioRestorative Therapies, Inc. | -10.41 Million USD | 26.322% |
| Apollomics, Inc. | -172.6 Million USD | 95.553% |
| Amarin Corporation plc | -59.11 Million USD | 87.015% |
| Mesoblast Limited | -87.95 Million USD | 91.273% |
| Turnstone Biologics Corp. | -55.2 Million USD | 86.095% |
| Kymera Therapeutics, Inc. | -146.96 Million USD | 94.777% |
| Synaptogenix, Inc. | -6.03 Million USD | -27.11% |
| Tiziana Life Sciences Ltd | -16.2 Million USD | 52.643% |
| Aurinia Pharmaceuticals Inc. | -78.02 Million USD | 90.162% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -60.192% |
| Monopar Therapeutics Inc. | -8.4 Million USD | 8.648% |
| Exelixis, Inc. | 207.76 Million USD | 103.694% |
| Better Therapeutics, Inc. | -39.76 Million USD | 80.695% |
| Nurix Therapeutics, Inc. | -143.94 Million USD | 94.668% |
| Apellis Pharmaceuticals, Inc. | -528.62 Million USD | 98.548% |
| NLS Pharmaceutics AG | -12.17 Million USD | 36.941% |
| Dermata Therapeutics, Inc. | -7.79 Million USD | 1.528% |
| Aridis Pharmaceuticals, Inc. | -30.74 Million USD | 75.038% |
| Gritstone bio, Inc. | -138.49 Million USD | 94.458% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 88.093% |
| TNF Pharmaceuticals, Inc. | -3.99 Million USD | -91.891% |
| Avid Bioservices, Inc. | -140.75 Million USD | 94.547% |
| Insmed Incorporated | -749.56 Million USD | 98.976% |
| Virpax Pharmaceuticals, Inc. | -15.18 Million USD | 49.468% |
| MediWound Ltd. | -6.71 Million USD | -14.288% |
| OmniAb, Inc. | -50.61 Million USD | 84.837% |
| Alector, Inc. | -130.39 Million USD | 94.113% |
| Seres Therapeutics, Inc. | -113.72 Million USD | 93.251% |
| Checkpoint Therapeutics, Inc. | -51.84 Million USD | 85.196% |
| Zai Lab Limited | -334.62 Million USD | 97.706% |
| Revance Therapeutics, Inc. | -323.98 Million USD | 97.631% |
| Aura Biosciences, Inc. | -76.4 Million USD | 89.955% |
| Lyell Immunopharma, Inc. | -234.63 Million USD | 96.729% |
| Immunic, Inc. | -93.61 Million USD | 91.801% |
| Tarsus Pharmaceuticals, Inc. | -135.89 Million USD | 94.352% |
| Veracyte, Inc. | -74.4 Million USD | 89.684% |
| FibroGen, Inc. | -284.23 Million USD | 97.3% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 70.74% |
| Adial Pharmaceuticals, Inc. | -7 Million USD | -9.621% |
| Sonnet BioTherapeutics Holdings, Inc. | -18.83 Million USD | 59.243% |
| Jazz Pharmaceuticals plc | 414.83 Million USD | 101.85% |
| Cyclacel Pharmaceuticals, Inc. | -22.55 Million USD | 65.97% |
| Amylyx Pharmaceuticals, Inc. | 49.27 Million USD | 115.578% |
| TG Therapeutics, Inc. | 12.67 Million USD | 160.571% |
| Galecto, Inc. | -38.34 Million USD | 79.985% |
| Calithera Biosciences, Inc. | -18.86 Million USD | 59.315% |
| Fortrea Holdings Inc. | -3.4 Million USD | -125.751% |
| KalVista Pharmaceuticals, Inc. | -126.64 Million USD | 93.939% |
| Aptevo Therapeutics Inc. | -17.41 Million USD | 55.916% |
| XBiotech Inc. | -24.55 Million USD | 68.744% |
| Jasper Therapeutics, Inc. | -64.46 Million USD | 88.093% |
| Lyra Therapeutics, Inc. | -62.68 Million USD | 87.754% |
| Foghorn Therapeutics Inc. | -98.42 Million USD | 92.202% |
| Y-mAbs Therapeutics, Inc. | -21.42 Million USD | 64.178% |
| Theravance Biopharma, Inc. | -55.19 Million USD | 86.093% |
| Ultragenyx Pharmaceutical Inc. | -606.63 Million USD | 98.735% |
| Metagenomi, Inc. Common Stock | -68.25 Million USD | 88.755% |
| Vaxxinity, Inc. | -56.93 Thousand USD | -13381.487% |
| BioCryst Pharmaceuticals, Inc. | -226.53 Million USD | 96.612% |
| Gain Therapeutics, Inc. | -22.26 Million USD | 65.53% |
| Cartesian Therapeutics, Inc. | -219.71 Million USD | 96.507% |
| NexImmune, Inc. | -32.34 Million USD | 76.269% |
| Creative Medical Technology Holdings, Inc. | -5.28 Million USD | -45.189% |
| Marker Therapeutics, Inc. | -14.04 Million USD | 45.354% |
| Regeneron Pharmaceuticals, Inc. | 3.95 Billion USD | 100.194% |
| Chemomab Therapeutics Ltd. | -24.22 Million USD | 68.31% |
| Scopus BioPharma Inc. | -11.6 Million USD | 33.887% |
| RAPT Therapeutics, Inc. | -116.79 Million USD | 93.428% |
| Ainos, Inc. | -13.77 Million USD | 44.261% |
| Pluri Inc. | -20.88 Million USD | 63.254% |
| Prothena Corporation plc | -147.02 Million USD | 94.78% |
| Adaptimmune Therapeutics plc | -113.87 Million USD | 93.259% |
| Celularity Inc. | -196.29 Million USD | 96.09% |
| Rallybio Corporation | -74.56 Million USD | 89.706% |
| Cue Biopharma, Inc. | -50.73 Million USD | 84.871% |
| MeiraGTx Holdings plc | -84.02 Million USD | 90.865% |
| Omeros Corporation | -117.81 Million USD | 93.485% |
| Humacyte, Inc. | -110.77 Million USD | 93.071% |
| Immunocore Holdings plc | -55.28 Million USD | 86.117% |
| Cocrystal Pharma, Inc. | -17.98 Million USD | 57.32% |
| Cidara Therapeutics, Inc. | -22.93 Million USD | 66.528% |
| Blueprint Medicines Corporation | -506.98 Million USD | 98.486% |
| CalciMedica, Inc. | -34.35 Million USD | 77.659% |
| Cabaletta Bio, Inc. | -67.67 Million USD | 88.658% |
| Marinus Pharmaceuticals, Inc. | -141.4 Million USD | 94.572% |
| Scholar Rock Holding Corporation | -165.78 Million USD | 95.37% |
| Sana Biotechnology, Inc. | -283.25 Million USD | 97.29% |
| Pulmatrix, Inc. | -14.12 Million USD | 45.644% |
| Elicio Therapeutics, Inc. | -35.19 Million USD | 78.191% |
| Vigil Neuroscience, Inc. | -82.63 Million USD | 90.712% |
| Intellia Therapeutics, Inc. | -481.19 Million USD | 98.405% |
| Adlai Nortye Ltd. American Depositary Shares | -104.87 Million USD | 92.681% |
| Cytokinetics, Incorporated | -526.24 Million USD | 98.541% |
| Eloxx Pharmaceuticals, Inc. | -36.06 Million USD | 78.717% |
| Nutriband Inc. | -5.48 Million USD | -39.929% |
| Protara Therapeutics, Inc. | -40.42 Million USD | 81.011% |
| Vor Biopharma Inc. | -117.86 Million USD | 93.488% |
| Roivant Sciences Ltd. | 4.34 Billion USD | 100.176% |
| Evogene Ltd. | -23.87 Million USD | 67.856% |
| ProKidney Corp. | -35.46 Million USD | 78.359% |
| Applied Therapeutics, Inc. | -119.76 Million USD | 93.591% |
| Hoth Therapeutics, Inc. | -7.84 Million USD | 2.165% |
| BridgeBio Pharma, Inc. | -643.2 Million USD | 98.807% |
| CorMedix Inc. | -46.33 Million USD | 83.436% |
| BioLineRx Ltd. | -60.61 Million USD | 87.337% |
| Tango Therapeutics, Inc. | -101.74 Million USD | 92.456% |
| Galectin Therapeutics Inc. | -41.06 Million USD | 81.309% |
| Atai Life Sciences N.V. | -40.22 Million USD | 80.918% |
| Renovaro Biosciences Inc. | -80.65 Million USD | 90.483% |
| Aerovate Therapeutics, Inc. | -75.52 Million USD | 89.837% |
| Zentalis Pharmaceuticals, Inc. | -292.19 Million USD | 97.373% |
| Sagimet Biosciences Inc. | -27.87 Million USD | 72.465% |
| MediciNova, Inc. | -8.57 Million USD | 10.453% |
| Praxis Precision Medicines, Inc. | -123.27 Million USD | 93.774% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 8.372% |
| GeoVax Labs, Inc. | -25.96 Million USD | 70.441% |
| Axsome Therapeutics, Inc. | -239.23 Million USD | 96.792% |
| Biomea Fusion, Inc. | -117.25 Million USD | 93.454% |
| PTC Therapeutics, Inc. | -626.6 Million USD | 98.775% |
| Mereo BioPharma Group plc | -29.46 Million USD | 73.951% |
| Cullinan Oncology, Inc. | -153.16 Million USD | 94.989% |
| Syndax Pharmaceuticals, Inc. | -209.36 Million USD | 96.334% |
| Absci Corporation | -110.56 Million USD | 93.058% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 74.542% |
| 4D Molecular Therapeutics, Inc. | -100.83 Million USD | 92.388% |
| Dyne Therapeutics, Inc. | -235.93 Million USD | 96.747% |
| Kiniksa Pharmaceuticals, Ltd. | 14.08 Million USD | 154.498% |
| Ventyx Biosciences, Inc. | -192.96 Million USD | 96.022% |
| Allakos Inc. | -185.7 Million USD | 95.867% |
| Imunon, Inc. | -19.51 Million USD | 60.668% |
| Fulcrum Therapeutics, Inc. | -97.33 Million USD | 92.114% |
| Corcept Therapeutics Incorporated | 106.14 Million USD | 107.232% |
| BioAtla, Inc. | -123.46 Million USD | 93.783% |
| NLS Pharmaceutics AG | -12.17 Million USD | 36.941% |
| Bio-Path Holdings, Inc. | -16.07 Million USD | 52.261% |
| Allogene Therapeutics, Inc. | -327.26 Million USD | 97.655% |
| Larimar Therapeutics, Inc. | -36.94 Million USD | 79.227% |
| XOMA Corporation | -40.83 Million USD | 81.202% |
| Kezar Life Sciences, Inc. | -101.87 Million USD | 92.465% |
| Cara Therapeutics, Inc. | -118.51 Million USD | 93.523% |
| aTyr Pharma, Inc. | -50.38 Million USD | 84.767% |
| Aligos Therapeutics, Inc. | -87.67 Million USD | 91.246% |
| Akero Therapeutics, Inc. | -151.75 Million USD | 94.942% |
| Viridian Therapeutics, Inc. | -237.73 Million USD | 96.771% |
| Eliem Therapeutics, Inc. | -35.11 Million USD | 78.144% |
| EyeGate Pharmaceuticals, Inc. | -8.09 Million USD | 5.146% |
| Akari Therapeutics, Plc | -10 Million USD | 23.306% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -11300.743% |
| Halozyme Therapeutics, Inc. | 281.59 Million USD | 102.726% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -15.164% |
| UroGen Pharma Ltd. | -102.24 Million USD | 92.493% |
| Sutro Biopharma, Inc. | -106.79 Million USD | 92.813% |
| ZIVO Bioscience, Inc. | -7.77 Million USD | 1.307% |
| Orgenesis Inc. | -55.36 Million USD | 86.135% |
| Entera Bio Ltd. | -8.88 Million USD | 13.651% |
| GH Research PLC | -35.58 Million USD | 78.432% |
| Lisata Therapeutics, Inc. | -20.84 Million USD | 63.169% |
| Reneo Pharmaceuticals, Inc. | -77.38 Million USD | 90.082% |
| Xencor, Inc. | -126.08 Million USD | 93.912% |
| 60 Degrees Pharmaceuticals, Inc. | -3.76 Million USD | -103.828% |
| Replimune Group, Inc. | -215.79 Million USD | 96.443% |
| Coeptis Therapeutics Holdings, Inc. | -21.26 Million USD | 63.908% |
| Vanda Pharmaceuticals Inc. | 2.5 Million USD | 405.921% |
| Lexaria Bioscience Corp. | -6.66 Million USD | -15.164% |
| Portage Biotech Inc. | -75.33 Million USD | 89.812% |
| Cardio Diagnostics Holdings, Inc. | -8.37 Million USD | 8.372% |
| Olema Pharmaceuticals, Inc. | -96.65 Million USD | 92.059% |
| OncoCyte Corporation | -27.78 Million USD | 72.371% |
| Qualigen Therapeutics, Inc. | -13.41 Million USD | 42.793% |
| Processa Pharmaceuticals, Inc. | -11.12 Million USD | 30.985% |
| Purple Biotech Ltd. | -19.88 Million USD | 61.391% |
| CollPlant Biotechnologies Ltd. | -7.01 Million USD | -9.354% |
| scPharmaceuticals Inc. | -54.81 Million USD | 85.996% |
| ProMIS Neurosciences, Inc. | -17.5 Million USD | 56.155% |
| HilleVax, Inc. | -123.56 Million USD | 93.788% |
| NeuroSense Therapeutics Ltd. | -10.1 Million USD | 24.057% |
| Tharimmune, Inc. | -9.31 Million USD | 17.636% |
| Genprex, Inc. | -30.86 Million USD | 75.128% |
| Neumora Therapeutics, Inc. Common Stock | -235.92 Million USD | 96.747% |
| Atossa Therapeutics, Inc. | -30.09 Million USD | 74.495% |
| XTL Biopharmaceuticals Ltd. | -1.78 Million USD | -330.727% |
| Virios Therapeutics, Inc. | -5.29 Million USD | -44.931% |
| OKYO Pharma Limited | -16.82 Thousand USD | -45518.664% |
| Savara Inc. | -54.69 Million USD | 85.967% |
| Curis, Inc. | -47.41 Million USD | 83.811% |
| Daré Bioscience, Inc. | -30.16 Million USD | 74.552% |
| Carmell Therapeutics Corporation | -15.44 Million USD | 50.304% |
| Titan Pharmaceuticals, Inc. | -5.56 Million USD | -37.826% |
| Achieve Life Sciences, Inc. | -29.81 Million USD | 74.256% |
| BeiGene, Ltd. | -881.7 Million USD | 99.129% |
| Kiromic BioPharma, Inc. | -21.29 Million USD | 63.954% |
| Revolution Medicines, Inc. Warrant | -436.36 Million USD | 98.241% |
| Protagonist Therapeutics, Inc. | -78.95 Million USD | 90.279% |
| Erasca, Inc. | -125.04 Million USD | 93.862% |
| bluebird bio, Inc. | -211.91 Million USD | 96.378% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -53.496% |
| BioMarin Pharmaceutical Inc. | 167.64 Million USD | 104.578% |
| DBV Technologies S.A. | -72.72 Million USD | 89.446% |
| Protagenic Therapeutics, Inc. | -5 Million USD | -53.496% |
| Moderna, Inc. | -4.71 Billion USD | 99.837% |
| Vincerx Pharma, Inc. | -40.15 Million USD | 80.886% |
| Fresh Tracks Therapeutics, Inc. | -5.69 Million USD | -34.801% |
| Molecular Templates, Inc. | -8.12 Million USD | 5.52% |
| Acrivon Therapeutics, Inc. Common Stock | -60.38 Million USD | 87.29% |
| Travere Therapeutics, Inc. | -111.39 Million USD | 93.11% |
| Monte Rosa Therapeutics, Inc. | -135.35 Million USD | 94.329% |
| Spruce Biosciences, Inc. | -47.91 Million USD | 83.982% |
| Celldex Therapeutics, Inc. | -141.42 Million USD | 94.573% |
| Cogent Biosciences, Inc. | -192.41 Million USD | 96.011% |
| MacroGenics, Inc. | -9.05 Million USD | 15.262% |
| RenovoRx, Inc. | -10.23 Million USD | 24.985% |
| Adicet Bio, Inc. | -142.65 Million USD | 94.62% |
| Prime Medicine, Inc. | -198.13 Million USD | 96.126% |
| Aditxt, Inc. | -32.38 Million USD | 76.296% |
| Adagene Inc. | -18.94 Million USD | 59.488% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -4.976% |
| Quantum-Si incorporated | -95.96 Million USD | 92.001% |
| Maravai LifeSciences Holdings, Inc. | -119.02 Million USD | 93.552% |
| Acurx Pharmaceuticals, Inc. | -14.57 Million USD | 47.348% |
| Voyager Therapeutics, Inc. | 132.33 Million USD | 105.8% |
| SciSparc Ltd. | -5.12 Million USD | -49.855% |
| Vericel Corporation | -3.18 Million USD | -141.218% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -6282.781% |
| Minerva Neurosciences, Inc. | -30 Million USD | 74.419% |
| Generation Bio Co. | -126.61 Million USD | 93.938% |
| Astria Therapeutics, Inc. | -72.89 Million USD | 89.47% |
| Black Diamond Therapeutics, Inc. | -82.44 Million USD | 90.69% |
| Arcutis Biotherapeutics, Inc. | -262.14 Million USD | 97.072% |
| Invivyd, Inc. | -198.64 Million USD | 96.136% |
| Relay Therapeutics, Inc. | -341.97 Million USD | 97.756% |
| Quoin Pharmaceuticals, Ltd. | -8.68 Million USD | 11.639% |
| Spero Therapeutics, Inc. | 22.8 Million USD | 133.656% |
| Artelo Biosciences, Inc. | -9.87 Million USD | 22.265% |
| 2seventy bio, Inc. | -217.57 Million USD | 96.472% |
| ADMA Biologics, Inc. | -28.23 Million USD | 72.819% |
| Clene Inc. | -49.5 Million USD | 84.495% |
| Capricor Therapeutics, Inc. | -22.28 Million USD | 65.561% |
| Boundless Bio, Inc. Common Stock | -49.43 Million USD | 84.473% |
| GeoVax Labs, Inc. | -25.96 Million USD | 70.441% |
| Recursion Pharmaceuticals, Inc. | -328.06 Million USD | 97.66% |
| Citius Pharmaceuticals, Inc. | -32.54 Million USD | 76.414% |
| Contineum Therapeutics, Inc. Class A Common Stock | 22.72 Million USD | 133.783% |
| Relmada Therapeutics, Inc. | -98.79 Million USD | 92.231% |
| Finch Therapeutics Group, Inc. | -74.75 Million USD | 89.732% |
| ALX Oncology Holdings Inc. | -160.8 Million USD | 95.227% |
| Vir Biotechnology, Inc. | -615.06 Million USD | 98.752% |
| Evaxion Biotech A/S | -22.12 Million USD | 65.308% |
| Ocular Therapeutix, Inc. | -80.73 Million USD | 90.493% |
| Verve Therapeutics, Inc. | -200.06 Million USD | 96.164% |
| Trevena, Inc. | -40.28 Million USD | 80.949% |
| Surrozen, Inc. | -43.04 Million USD | 82.167% |
| Tyra Biosciences, Inc. | -69.13 Million USD | 88.898% |
| Cingulate Inc. | -23.53 Million USD | 67.387% |
| Galmed Pharmaceuticals Ltd. | -6.91 Million USD | -11.047% |
| Unity Biotechnology, Inc. | -39.86 Million USD | 80.744% |
| Tenax Therapeutics, Inc. | -7.71 Million USD | 0.456% |
| Terns Pharmaceuticals, Inc. | -90.21 Million USD | 91.491% |
| ACADIA Pharmaceuticals Inc. | -61.28 Million USD | 87.476% |
| Connect Biopharma Holdings Limited | -59.5 Million USD | 87.101% |
| Clearmind Medicine Inc. | -11.95 Million USD | 35.796% |
| Kronos Bio, Inc. | -112.67 Million USD | 93.188% |
| Bolt Biotherapeutics, Inc. | -69.19 Million USD | 88.908% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -302536.196% |
| Viking Therapeutics, Inc. | -85.89 Million USD | 91.064% |
| Statera Biopharma, Inc. | -174.4 Million USD | 95.599% |
| ImmunityBio, Inc. | -583.19 Million USD | 98.684% |
| Korro Bio, Inc. | -81.17 Million USD | 90.544% |
| Kineta, Inc. | -14.09 Million USD | 45.56% |
| BioVie Inc. | -32.12 Million USD | 76.104% |
| Codexis, Inc. | -76.24 Million USD | 89.932% |
| Celularity Inc. | -196.29 Million USD | 96.09% |
| Crinetics Pharmaceuticals, Inc. | -214.52 Million USD | 96.422% |
| Celcuity Inc. | -63.77 Million USD | 87.965% |
| Virax Biolabs Group Limited | -6.73 Million USD | -13.99% |
| Cibus, Inc. | -267.62 Million USD | 97.132% |
| Eledon Pharmaceuticals, Inc. | -40.32 Million USD | 80.966% |
| eFFECTOR Therapeutics, Inc. | -35.81 Million USD | 78.567% |
| IN8bio, Inc. | -30 Million USD | 74.421% |
| Kodiak Sciences Inc. | -260.49 Million USD | 97.053% |
| Annexon, Inc. | -134.23 Million USD | 94.282% |
| Adverum Biotechnologies, Inc. | -117.16 Million USD | 93.449% |
| Assembly Biosciences, Inc. | -61.22 Million USD | 87.464% |
| Avalo Therapeutics, Inc. | -31.54 Million USD | 75.667% |
| Ionis Pharmaceuticals, Inc. | -366.28 Million USD | 97.904% |
| Eyenovia, Inc. | -27.26 Million USD | 71.844% |
| Puma Biotechnology, Inc. | 21.59 Million USD | 135.55% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -1334.682% |
| Xilio Therapeutics, Inc. | -76.4 Million USD | 89.954% |
| Arcellx, Inc. | -70.69 Million USD | 89.142% |
| Cardiff Oncology, Inc. | -41.44 Million USD | 81.478% |
| Enanta Pharmaceuticals, Inc. | -133.81 Million USD | 94.264% |
| Regulus Therapeutics Inc. | -30.03 Million USD | 74.446% |
| Moolec Science SA | -51.78 Million USD | 85.179% |
| Acumen Pharmaceuticals, Inc. | -52.37 Million USD | 85.344% |
| Geron Corporation | -184.12 Million USD | 95.831% |
| LAVA Therapeutics N.V. | -41.97 Million USD | 81.714% |
| Royalty Pharma plc | 1.13 Billion USD | 100.676% |
| Atea Pharmaceuticals, Inc. | -135.95 Million USD | 94.354% |
| Greenwich LifeSciences, Inc. | -8.89 Million USD | 13.678% |
| TFF Pharmaceuticals, Inc. | -21.24 Million USD | 63.868% |
| Mersana Therapeutics, Inc. | -171.67 Million USD | 95.529% |
| Humacyte, Inc. | -110.77 Million USD | 93.071% |
| Structure Therapeutics Inc. | -89.62 Million USD | 91.435% |
| 89bio, Inc. | -142.18 Million USD | 94.602% |
| PMV Pharmaceuticals, Inc. | -68.96 Million USD | 88.87% |
| Avenue Therapeutics, Inc. | -10.37 Million USD | 26.033% |
| Genelux Corporation | -28.29 Million USD | 72.875% |
| Trevi Therapeutics, Inc. | -29.06 Million USD | 73.592% |
| Lexicon Pharmaceuticals, Inc. | -177.11 Million USD | 95.666% |
| Notable Labs, Ltd. | -11.26 Million USD | 31.858% |
| Liquidia Corporation | -78.5 Million USD | 90.222% |
| Mustang Bio, Inc. | -51.6 Million USD | 85.125% |
| Immunovant, Inc. | -259.33 Million USD | 97.04% |
| Quantum-Si incorporated | -95.96 Million USD | 92.001% |
| Arbutus Biopharma Corporation | -72.84 Million USD | 89.464% |
| DiaMedica Therapeutics Inc. | -19.38 Million USD | 60.397% |
| Vera Therapeutics, Inc. | -95.99 Million USD | 92.004% |
| Acasti Pharma Inc. | -12.85 Million USD | 40.282% |
| MiNK Therapeutics, Inc. | -22.45 Million USD | 65.822% |
| Pasithea Therapeutics Corp. | -15.96 Million USD | 51.913% |
| Xenon Pharmaceuticals Inc. | -182.39 Million USD | 95.792% |
| Elevai Labs, Inc. Common Stock | -4.3 Million USD | -78.438% |
| NeuroBo Pharmaceuticals, Inc. | -12.47 Million USD | 38.448% |
| Tempest Therapeutics, Inc. | -29.49 Million USD | 73.973% |
| Soleno Therapeutics, Inc. | -38.98 Million USD | 80.313% |
| PepGen Inc. | -78.62 Million USD | 90.238% |
| Moleculin Biotech, Inc. | -29.76 Million USD | 74.216% |
| United Therapeutics Corporation | 984.8 Million USD | 100.779% |
| Nuvectis Pharma, Inc. | -22.26 Million USD | 65.519% |
| Solid Biosciences Inc. | -96.01 Million USD | 92.006% |
| BriaCell Therapeutics Corp. | -4.79 Million USD | -60.192% |
| Immuneering Corporation | -53.47 Million USD | 85.646% |
| Lixte Biotechnology Holdings, Inc. | -5.08 Million USD | -50.885% |
| Silo Pharma, Inc. | -3.7 Million USD | -107.409% |
| Belite Bio, Inc | -31.63 Million USD | 75.735% |
| XOMA Corporation | -40.83 Million USD | 81.202% |
| ARS Pharmaceuticals, Inc. | -54.36 Million USD | 85.881% |
| Bionomics Limited | -15.49 Billion USD | 99.95% |
| Apogee Therapeutics, Inc. | -83.98 Million USD | 90.861% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 73.675% |
| uniQure N.V. | -308.47 Million USD | 97.512% |
| Cassava Sciences, Inc. | -97.21 Million USD | 92.105% |
| Estrella Immunopharma, Inc. | -7.31 Million USD | -4.976% |
| Poseida Therapeutics, Inc. | -123.43 Million USD | 93.781% |
| Forte Biosciences, Inc. | -31.47 Million USD | 75.615% |
| Anebulo Pharmaceuticals, Inc. | -8.2 Million USD | 6.415% |
| Enlivex Therapeutics Ltd. | -29.06 Million USD | 73.595% |
| Conduit Pharmaceuticals Inc. | -535 Thousand USD | -1334.682% |
| SeaStar Medical Holding Corporation | -26.23 Million USD | 70.74% |
| FibroBiologics, Inc. Common Stock | -16.48 Million USD | 53.439% |
| Altimmune, Inc. | -88.44 Million USD | 91.322% |
| Amicus Therapeutics, Inc. | -151.58 Million USD | 94.936% |
| Alpha Tau Medical Ltd. | -29.15 Million USD | 73.675% |
| Compugen Ltd. | -18.75 Million USD | 59.072% |
| Peak Bio, Inc. | -1259.26 USD | -609428.612% |
| Zevra Therapeutics, Inc. | -46.04 Million USD | 83.332% |
| Benitec Biopharma Inc. | -21.75 Million USD | 64.712% |
| Spyre Therapeutics, Inc. | -338.79 Million USD | 97.734% |
| NKGen Biotech, Inc. Common Stock | -82.95 Million USD | 90.747% |
| Zura Bio Limited | -60.36 Million USD | 87.284% |
| PolyPid Ltd. | -23.86 Million USD | 67.838% |
| Aileron Therapeutics, Inc. | -15.73 Million USD | 51.211% |
| NKGen Biotech, Inc. Warrants | -82.95 Million USD | 90.747% |
| Instil Bio, Inc. | -156.08 Million USD | 95.083% |
| argenx SE | -295.05 Million USD | 97.399% |
| Immunome, Inc. | -106.8 Million USD | 92.814% |
| Compass Therapeutics, Inc. | -42.49 Million USD | 81.937% |
| Verona Pharma plc | -54.36 Million USD | 85.882% |
| enGene Holdings Inc. Warrants | -99.91 Million USD | 92.318% |
| Shattuck Labs, Inc. | -87.29 Million USD | 91.208% |
| CervoMed Inc. | -2.17 Million USD | -253.407% |
| LENZ Therapeutics, Inc. | -124.65 Million USD | 93.842% |
| Plus Therapeutics, Inc. | -13.31 Million USD | 42.358% |
| Dianthus Therapeutics, Inc. | -43.55 Million USD | 82.377% |
| Moolec Science SA | -51.78 Million USD | 85.179% |
| Enveric Biosciences, Inc. | -17.29 Thousand USD | -44288.56% |
| Inovio Pharmaceuticals, Inc. | -135.11 Million USD | 94.319% |
| AnaptysBio, Inc. | -163.61 Million USD | 95.309% |
| Design Therapeutics, Inc. | -66.86 Million USD | 88.52% |
| Leap Therapeutics, Inc. | -81.41 Million USD | 90.572% |
| NeurAxis, Inc. | -14.62 Million USD | 47.524% |
| Seelos Therapeutics, Inc. | -37.88 Million USD | 79.738% |
| Lumos Pharma, Inc. | -34.03 Million USD | 77.447% |
| Achilles Therapeutics plc | -69.66 Million USD | 88.982% |
| enGene Holdings Inc. Common Stock | -99.91 Million USD | 92.318% |
| 180 Life Sciences Corp. | -19.93 Million USD | 61.497% |
| Opiant Pharmaceuticals, Inc. | 3 Million USD | 355.104% |
| CERo Therapeutics Holdings, Inc. | -2536.23 USD | -302536.196% |
| Nutriband Inc. | -5.48 Million USD | -39.929% |
| ORIC Pharmaceuticals, Inc. | -100.69 Million USD | 92.378% |
| CG Oncology, Inc. Common stock | -48.6 Million USD | 84.209% |
| Fractyl Health, Inc. Common Stock | -77.09 Million USD | 90.044% |
| Rani Therapeutics Holdings, Inc. | -33.97 Million USD | 77.405% |
| MoonLake Immunotherapeutics | -36 Million USD | 78.683% |
| Palisade Bio, Inc. | -12.3 Million USD | 37.597% |
| Tourmaline Bio, Inc. | -42.12 Million USD | 81.779% |
| Beam Therapeutics Inc. | -132.52 Million USD | 94.208% |
| Neurogene Inc. | -36.31 Million USD | 78.865% |
| Mirum Pharmaceuticals, Inc. | -163.41 Million USD | 95.303% |
| AEON Biopharma, Inc. | -52.55 Million USD | 85.395% |
| CARGO Therapeutics, Inc. Common Stock | -98.14 Million USD | 92.18% |
| Sesen Bio, Inc. | -19.88 Million USD | 61.398% |
| Enliven Therapeutics, Inc. | -71.58 Million USD | 89.278% |
| Kiora Pharmaceuticals, Inc. | -12.51 Million USD | 38.664% |
| Iovance Biotherapeutics, Inc. | -444.03 Million USD | 98.271% |
| Taysha Gene Therapies, Inc. | -111.56 Million USD | 93.12% |
| Athira Pharma, Inc. | -117.67 Million USD | 93.477% |
| Vaccinex, Inc. | -20.25 Million USD | 62.098% |
| HCW Biologics Inc. | -24.99 Million USD | 69.291% |
| XOMA Corporation | -40.83 Million USD | 81.202% |
| Nektar Therapeutics | -276.05 Million USD | 97.22% |
| Arvinas, Inc. | -367.3 Million USD | 97.91% |
| Tevogen Bio Holdings Inc. | -67.32 Thousand USD | -11300.743% |
| Merus N.V. | -154.93 Million USD | 95.046% |
| Omega Therapeutics, Inc. | -97.42 Million USD | 92.122% |
| Quince Therapeutics, Inc. | -31.38 Million USD | 75.544% |
| Rezolute, Inc. | -68.45 Million USD | 88.788% |
| Clene Inc. | -49.5 Million USD | 84.495% |
| Indaptus Therapeutics, Inc. | -15.42 Million USD | 50.235% |
| BeyondSpring Inc. | -21.02 Million USD | 63.495% |
| Synlogic, Inc. | -57.28 Million USD | 86.6% |
| Allarity Therapeutics, Inc. | -11.9 Million USD | 35.505% |
| Phio Pharmaceuticals Corp. | -10.82 Million USD | 29.101% |
| Peak Bio, Inc. | -1259.26 USD | -609428.612% |
| Werewolf Therapeutics, Inc. | -37.36 Million USD | 79.46% |
| Krystal Biotech, Inc. | 10.93 Million USD | 170.212% |
| Karyopharm Therapeutics Inc. | -143.09 Million USD | 94.636% |
| SpringWorks Therapeutics, Inc. | -325.1 Million USD | 97.639% |
| Lipella Pharmaceuticals Inc. | -4.61 Million USD | -66.175% |
| MannKind Corporation | -11.93 Million USD | 35.705% |
| Ikena Oncology, Inc. | -68.16 Million USD | 88.74% |
| Cyclerion Therapeutics, Inc. | -21.01 Million USD | 63.476% |
| Gyre Therapeutics, Inc. | -92.93 Million USD | 91.741% |
| Gossamer Bio, Inc. | -179.81 Million USD | 95.731% |
| CohBar, Inc. | -11.96 Million USD | 35.835% |
| Cognition Therapeutics, Inc. | -25.78 Million USD | 70.236% |
| NRx Pharmaceuticals, Inc. | -30.15 Million USD | 74.542% |
| Legend Biotech Corporation | -518.25 Million USD | 98.519% |
| Mural Oncology plc | -207.44 Million USD | 96.3% |
| Biora Therapeutics, Inc. | -124.11 Million USD | 93.816% |
| PaxMedica, Inc. Common Stock | -18.28 Million USD | 58.034% |
| Disc Medicine, Inc. | -76.42 Million USD | 89.957% |
| Champions Oncology, Inc. | -7.27 Million USD | -5.491% |
| REGENXBIO Inc. | -263.49 Million USD | 97.087% |
| Ensysce Biosciences, Inc. | -10.61 Million USD | 27.678% |
| Anavex Life Sciences Corp. | -47.5 Million USD | 83.843% |
| Cellectar Biosciences, Inc. | -37.98 Million USD | 79.792% |
| Edgewise Therapeutics, Inc. | -100.16 Million USD | 92.337% |
| Vaxart, Inc. | -82.46 Million USD | 90.692% |
| PharmaCyte Biotech, Inc. | 333.76 Thousand USD | 2399.701% |
| Aldeyra Therapeutics, Inc. | -37.54 Million USD | 79.555% |
| Cellectis S.A. | -101.05 Million USD | 92.405% |
| Longeveron Inc. | -21.41 Million USD | 64.155% |
| Repare Therapeutics Inc. | -93.79 Million USD | 91.817% |
| Sarepta Therapeutics, Inc. | -535.97 Million USD | 98.568% |
| Inozyme Pharma, Inc. | -71.16 Million USD | 89.215% |
| Revolution Medicines, Inc. | -436.36 Million USD | 98.241% |
| Nymox Pharmaceutical Corporation | -6.57 Million USD | -16.809% |
| Third Harmonic Bio, Inc. | -30.82 Million USD | 75.099% |
| ArriVent BioPharma, Inc. Common Stock | -69.33 Million USD | 88.929% |
| AN2 Therapeutics, Inc. | -64.73 Million USD | 88.143% |
| Anixa Biosciences, Inc. | -9.81 Million USD | 21.766% |
| Vertex Pharmaceuticals Incorporated | 3.61 Billion USD | 100.212% |
| Denali Therapeutics Inc. | -145.22 Million USD | 94.715% |
| Revelation Biosciences, Inc. | -120.25 Thousand USD | -6282.781% |
| Veru Inc. | -93.15 Million USD | 91.76% |
| Corvus Pharmaceuticals, Inc. | -27.02 Million USD | 71.603% |
| Cingulate Inc. | -23.53 Million USD | 67.387% |
| Passage Bio, Inc. | -102.06 Million USD | 92.48% |
| Context Therapeutics Inc. | -23.96 Million USD | 67.971% |
| Exicure, Inc. | -16.91 Million USD | 54.62% |
| Day One Biopharmaceuticals, Inc. | -188.91 Million USD | 95.937% |
| Oramed Pharmaceuticals Inc. | -37.76 Million USD | 79.675% |
| Scinai Immunotherapeutics Ltd. | -6.5 Million USD | -17.952% |
| Rhythm Pharmaceuticals, Inc. | -184.67 Million USD | 95.844% |
| Nuvalent, Inc. | -126.21 Million USD | 93.919% |
| ABVC BioPharma, Inc. | -10.51 Million USD | 27.008% |
| Carisma Therapeutics, Inc. | -86.87 Million USD | 91.165% |
| Unicycive Therapeutics, Inc. | -30.54 Million USD | 74.871% |
| OmniAb, Inc. | -50.61 Million USD | 84.837% |
| Anew Medical, Inc. | 1.34 Million USD | 670.196% |
| Fennec Pharmaceuticals Inc. | -16.04 Million USD | 52.162% |
| Lipocine Inc. | -16.35 Million USD | 53.061% |
| Lexeo Therapeutics, Inc. Common Stock | -66.39 Million USD | 88.439% |
| Nautilus Biotechnology, Inc. | -63.67 Million USD | 87.946% |
| SAB Biotherapeutics, Inc. | -42.19 Million USD | 81.809% |
| G1 Therapeutics, Inc. | -47.96 Million USD | 83.998% |
| Bellerophon Therapeutics, Inc. | -19.83 Million USD | 61.295% |
| Sage Therapeutics, Inc. | -541.48 Million USD | 98.583% |
| Ocugen, Inc. | -63.07 Million USD | 87.832% |
| Mind Medicine (MindMed) Inc. | -95.73 Million USD | 91.982% |
| Q32 Bio Inc. | -112.96 Million USD | 93.205% |
| Brainstorm Cell Therapeutics Inc. | -17.19 Million USD | 55.354% |
| Alumis Inc. Common Stock | -154.99 Million USD | 95.048% |
| Equillium, Inc. | -13.33 Million USD | 42.441% |
| Kyverna Therapeutics, Inc. | -60.36 Million USD | 87.285% |
| Coya Therapeutics, Inc. | -7.98 Million USD | 3.91% |
| CNS Pharmaceuticals, Inc. | -18.85 Million USD | 59.284% |
| Galera Therapeutics, Inc. | -59.08 Million USD | 87.009% |
| Evelo Biosciences, Inc. | -114.52 Million USD | 93.298% |
| Comera Life Sciences Holdings, Inc. | -18.37 Million USD | 58.235% |
| Dominari Holdings Inc. | -22.88 Million USD | 66.456% |
| Edesa Biotech, Inc. | -8.37 Million USD | 8.345% |
| vTv Therapeutics Inc. | -20.25 Million USD | 62.096% |
| Bio-Techne Corporation | 168.1 Million USD | 104.566% |
| Agios Pharmaceuticals, Inc. | -352.08 Million USD | 97.82% |
| Harmony Biosciences Holdings, Inc. | 128.85 Million USD | 105.957% |
| Prelude Therapeutics Incorporated | -121.83 Million USD | 93.7% |
| Candel Therapeutics, Inc. | -37.93 Million USD | 79.769% |
| iTeos Therapeutics, Inc. | -112.64 Million USD | 93.186% |
| Nkarta, Inc. | -117.5 Million USD | 93.468% |
| BioCardia, Inc. | -11.57 Million USD | 33.666% |
| Iterum Therapeutics plc | -38.37 Million USD | 79.996% |